Muscle wasting in disease: molecular mechanisms and promising therapies
暂无分享,去创建一个
[1] B. Kobilka,et al. Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by the β2‐adrenergic receptor , 2002, Muscle & nerve.
[2] J. Thissen,et al. Mechanisms of glucocorticoid-induced myopathy. , 2008, The Journal of endocrinology.
[3] W. Mitch,et al. Review of muscle wasting associated with chronic kidney disease. , 2010, The American journal of clinical nutrition.
[4] S. Powers,et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. , 2008, The New England journal of medicine.
[5] S. Kandarian,et al. The molecular basis of skeletal muscle atrophy. , 2004, American journal of physiology. Cell physiology.
[6] L. Larsson. Acute quadriplegic myopathy: an acquired "myosinopathy". , 2008, Advances in experimental medicine and biology.
[7] Marco Sandri,et al. Signaling in muscle atrophy and hypertrophy. , 2008, Physiology.
[8] T. Luedde,et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. , 2006, The Journal of clinical investigation.
[9] D. Glass,et al. Skeletal muscle hypertrophy and atrophy signaling pathways. , 2005, The international journal of biochemistry & cell biology.
[10] W. Mitch,et al. Caspase-3 Cleaves Specific 19 S Proteasome Subunits in Skeletal Muscle Stimulating Proteasome Activity* , 2010, The Journal of Biological Chemistry.
[11] A. Goldberg,et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.
[12] D. Breuillé,et al. Pentoxifylline improves insulin action limiting skeletal muscle catabolism after infection. , 1999, The Journal of endocrinology.
[13] D. Underwood,et al. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. , 2000, Current opinion in pulmonary medicine.
[14] A. Goldberg,et al. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. , 1995, The American journal of physiology.
[15] C. Lang,et al. Sepsis and AMPK Activation by AICAR Differentially Regulate FoxO-1, -3 and -4 mRNA in Striated Muscle. , 2008, International journal of clinical and experimental medicine.
[16] Hsin C. Lin,et al. Insulin-like Growth Factor-1 (IGF-1) Inversely Regulates Atrophy-induced Genes via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Pathway* , 2005, Journal of Biological Chemistry.
[17] S. Bhatnagar,et al. The TWEAK–Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice , 2010, The Journal of cell biology.
[18] L. Visser,et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients , 2001, Critical care medicine.
[19] W. Fiers,et al. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[20] S. Brachat,et al. An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy , 2013, Molecular and Cellular Biology.
[21] W. Mitch,et al. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. , 2006, Journal of the American Society of Nephrology : JASN.
[22] T. Zimmers,et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. , 2010, Biochemical and biophysical research communications.
[23] R. Ch.,et al. NUTRITION IN GERIATRICS. , 1963 .
[24] Christoph Handschin,et al. The role of exercise and PGC1α in inflammation and chronic disease , 2008, Nature.
[25] W. Frontera,et al. IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.
[26] L. Liang,et al. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. , 2010, The Journal of trauma.
[27] W. Mitch,et al. Mechanisms stimulating muscle wasting in chronic kidney disease: the roles of the ubiquitin-proteasome system and myostatin , 2013, Clinical and Experimental Nephrology.
[28] Steven J Brown,et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways , 2011, Proceedings of the National Academy of Sciences.
[29] Marco Sandri,et al. Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.
[30] W. Sibbald,et al. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barré syndrome. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[31] Marcus D. Goncalves,et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity , 2009, International Journal of Obesity.
[32] T. P. Neufeld,et al. Role and regulation of starvation-induced autophagy in the Drosophila fat body. , 2004, Developmental cell.
[33] K. Rabe. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease , 2011, British journal of pharmacology.
[34] A. Goldberg,et al. Muscle Wasting in Aged, Sarcopenic Rats Is Associated with Enhanced Activity of the Ubiquitin Proteasome Pathway* , 2010, The Journal of Biological Chemistry.
[35] S. Kandarian,et al. Rel A/p65 is required for cytokine-induced myotube atrophy. , 2012, American journal of physiology. Cell physiology.
[36] S. Bodine,et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. , 2008, American journal of physiology. Endocrinology and metabolism.
[37] A. Baccarelli,et al. Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects , 2001, Experimental Gerontology.
[38] P. Hasselgren,et al. PPARβ/δ Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting , 2013, PloS one.
[39] J. Granton,et al. Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension. , 2013, American journal of respiratory cell and molecular biology.
[40] D. Spina. Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease , 2012, Drugs.
[41] Susan C Kandarian,et al. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. , 2004, The Journal of clinical investigation.
[42] W. Mitch,et al. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. , 2009, The Journal of clinical investigation.
[43] P. Hasselgren,et al. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle , 2010, Journal of cellular biochemistry.
[44] Jiandie D. Lin,et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.
[45] Theresa A Lansdell,et al. Sensitization of tumor cells toward chemotherapy: enhancing the efficacy of camptothecin with imidazolines. , 2004, Chemistry & biology.
[46] S. Kuang,et al. Myostatin knockout drives browning of white adipose tissue through activating the AMPK‐PGC1α‐Fndc5 pathway in muscle , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[47] A. Isacchi,et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. , 2013, Nature chemical biology.
[48] F. Piette,et al. Sarcopenia is predictive of nosocomial infection in care of the elderly , 2006, British Journal of Nutrition.
[49] Yanjun Dong,et al. Myostatin Suppression of Akirin1 Mediates Glucocorticoid-Induced Satellite Cell Dysfunction , 2013, PloS one.
[50] P. Ponikowski,et al. Cachexia: a new definition. , 2008, Clinical nutrition.
[51] P. Elliott,et al. Sirtuins — novel therapeutic targets to treat age-associated diseases , 2008, Nature Reviews Drug Discovery.
[52] A. Goldberg,et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. , 2007, Cell metabolism.
[53] E. Hund. Myopathy in critically ill patients. , 1999, Critical care medicine.
[54] Nicholas Ling,et al. Prolonged absence of myostatin reduces sarcopenia , 2006, Journal of cellular physiology.
[55] D. Lacey,et al. Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.
[56] A. Goldberg,et al. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[57] M. J. Curran,et al. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. , 1999, Urology.
[58] A. Goldberg,et al. Identification of a Novel Pool of Extracellular Pro-myostatin in Skeletal Muscle* , 2008, Journal of Biological Chemistry.
[59] M. Decramer,et al. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD , 2009, European Respiratory Journal.
[60] F. Dunshea,et al. Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs. , 2002, The British journal of nutrition.
[61] M. Decramer,et al. Gene Expression Profiling in Vastus Lateralis Muscle During an Acute Exacerbation of COPD , 2010, Cellular Physiology and Biochemistry.
[62] Jared A Brown,et al. Clenbuterol toxicity: a NSW Poisons Information Centre experience , 2014, The Medical journal of Australia.
[63] Michael Karin,et al. The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.
[64] J. Walls,et al. Glucocorticoid antagonist RU38486 fails to block acid-induced muscle wasting in vivo or in vitro. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[65] R. Gerzer,et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. , 1991, Immunology.
[66] F. Villarroya,et al. SIRT1 Controls the Transcription of the Peroxisome Proliferator-activated Receptor-γ Co-activator-1α (PGC-1α) Gene in Skeletal Muscle through the PGC-1α Autoregulatory Loop and Interaction with MyoD* , 2009, The Journal of Biological Chemistry.
[67] G. Lynch,et al. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. , 2011, Journal of applied physiology.
[68] Shalender Bhasin,et al. Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[69] R. McCARTER,et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. , 1985, The Journal of clinical endocrinology and metabolism.
[70] Yi-Ping Li,et al. Tumor necrosis factor-α and muscle wasting: a cellular perspective , 2001, Respiratory research.
[71] J. Mendell,et al. Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates , 2009, Science Translational Medicine.
[72] W. Rottbauer,et al. JunB-CBFβ signaling is essential to maintain sarcomeric Z-disc structure and when defective leads to heart failure , 2010, Journal of Cell Science.
[73] S. Gygi,et al. Genomic and Proteomic Profiling Reveals Reduced Mitochondrial Function and Disruption of the Neuromuscular Junction Driving Rat Sarcopenia , 2012, Molecular and Cellular Biology.
[74] Sandhya Sriram,et al. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF‐κB , 2011, Aging cell.
[75] Wei Wei,et al. Role of glucocorticoids in the molecular regulation of muscle wasting , 2007, Critical care medicine.
[76] A. Goldberg,et al. Peroxisome Proliferator-activated Receptor γ Coactivator 1α or 1β Overexpression Inhibits Muscle Protein Degradation, Induction of Ubiquitin Ligases, and Disuse Atrophy* , 2010, The Journal of Biological Chemistry.
[77] S. Hatakeyama,et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. , 2009, American journal of physiology. Cell physiology.
[78] D. Taillandier,et al. Skeletal muscle proteolysis in aging , 2009, Current opinion in clinical nutrition and metabolic care.
[79] R. Ahima,et al. Functional improvement of dystrophic muscle by myostatin blockade , 2002, Nature.
[80] K. Nakashima,et al. AMPK Activation Stimulates Myofibrillar Protein Degradation and Expression of Atrophy-Related Ubiquitin Ligases by Increasing FOXO Transcription Factors in C2C12 Myotubes , 2007, Bioscience, biotechnology, and biochemistry.
[81] N. Offner,et al. The initiation factor eIF3‐f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy , 2008, The EMBO journal.
[82] An-fang Cui,et al. PGC-1 beta-regulated mitochondrial biogenesis and function in myotubes is mediated by NRF-1 and ERR alpha. , 2010, Mitochondrion.
[83] R. Casaburi,et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. , 2002, American journal of physiology. Endocrinology and metabolism.
[84] C. Loprinzi,et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). , 2010, Lung cancer.
[85] S. Dunlop,et al. Striking Denervation of Neuromuscular Junctions without Lumbar Motoneuron Loss in Geriatric Mouse Muscle , 2011, PloS one.
[86] Jie Du,et al. XIAP reduces muscle proteolysis induced by CKD. , 2010, Journal of the American Society of Nephrology : JASN.
[87] A. Russell,et al. Effect of resistance exercise contraction mode and protein supplementation on members of the STARS signalling pathway , 2013, The Journal of physiology.
[88] M. Sandri,et al. Posttranslational modifications control FoxO3 activity during denervation. , 2012, American journal of physiology. Cell physiology.
[89] A. Dobs,et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. , 2013, The Lancet. Oncology.
[90] S. Wing,et al. Mechanisms involved in 3',5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle. , 2009, Endocrinology.
[91] F. Booth,et al. Sirt1 increases skeletal muscle precursor cell proliferation. , 2009, European journal of cell biology.
[92] G. Schuler,et al. Exercise Training Attenuates MuRF-1 Expression in the Skeletal Muscle of Patients With Chronic Heart Failure Independent of Age: The Randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging Catabolism Study , 2012, Circulation.
[93] Claudine Jurkovitz,et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. , 1999, American journal of physiology. Cell physiology.
[94] P. Novotny,et al. A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome , 2007, Cancer.
[95] M. Deschenes,et al. Remodeling of the neuromuscular junction precedes sarcopenia related alterations in myofibers , 2010, Experimental Gerontology.
[96] C. Deng,et al. Recent progress in the biology and physiology of sirtuins , 2009, Nature.
[97] C. Greenberg,et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. , 2002, American journal of human genetics.
[98] S. Kandarian,et al. Inhibition of IkappaB kinase alpha (IKKα) or IKKbeta (IKKβ) plus forkhead box O (Foxo) abolishes skeletal muscle atrophy. , 2011, Biochemical and biophysical research communications.
[99] J. Fischer,et al. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. , 1999, Surgery.
[100] S. Gygi,et al. Trim32 reduces PI3K–Akt–FoxO signaling in muscle atrophy by promoting plakoglobin–PI3K dissociation , 2014, The Journal of cell biology.
[101] Ramesh Narayanan,et al. Selective androgen receptor modulators in preclinical and clinical development , 2008, Nuclear receptor signaling.
[102] R. Griggs,et al. Effect of testosterone on muscle mass and muscle protein synthesis. , 1989, Journal of applied physiology.
[103] W. Markesbery,et al. Possible involvement of proteasome inhibition in aging: implications for oxidative stress , 2000, Mechanisms of Ageing and Development.
[104] K. Matthews,et al. Myostatin, a transforming growth factor‐β superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct , 1999, Journal of cellular physiology.
[105] S. Bodine,et al. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. , 2007, Journal of applied physiology.
[106] F. Maltais,et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension , 2009, Thorax.
[107] Se-Jin Lee,et al. Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[108] A. Hatzelmann,et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.
[109] J. Schertzer,et al. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.
[110] Seumas McCroskery,et al. Myostatin negatively regulates satellite cell activation and self-renewal , 2003, The Journal of cell biology.
[111] C. Mammucari,et al. Smad2 and 3 transcription factors control muscle mass in adulthood. , 2009, American journal of physiology. Cell physiology.
[112] A. Goldberg,et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[113] L. Strindberg,et al. CYCLIC ADENOSINE MONOPHOSPHATE-PHOSPHODIESTERASE INHIBITORS REDUCE SKELETAL MUSCLE PROTEIN CATABOLISM IN SEPTIC RATS , 2007, Shock.
[114] W. Kraus,et al. Myostatin decreases with aerobic exercise and associates with insulin resistance. , 2010, Medicine and science in sports and exercise.
[115] M. Sandri,et al. Cellular and molecular mechanisms of muscle atrophy , 2013, Disease Models & Mechanisms.
[116] Richard T. Lee,et al. Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.
[117] R. Porcher,et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease , 2006, Thorax.
[118] M. Woo,et al. Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy. , 2009, Journal of applied physiology.
[119] S. Gygi,et al. An AMPK-FOXO Pathway Mediates Longevity Induced by a Novel Method of Dietary Restriction in C. elegans , 2007, Current Biology.
[120] S. Geuna,et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. , 2013, The Journal of clinical investigation.
[121] A. Vermeulen. Clinical review 24: Androgens in the aging male. , 1991, The Journal of clinical endocrinology and metabolism.
[122] E. Kudryashova,et al. Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component. , 2009, Human molecular genetics.
[123] G. Supinski,et al. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[124] F. López‐Soriano,et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance , 2011, Journal of cachexia, sarcopenia and muscle.
[125] J. Dalton,et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial , 2011, Journal of cachexia, sarcopenia and muscle.
[126] N. Møller,et al. Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects. , 2013, American journal of physiology. Endocrinology and metabolism.
[127] J. Qin,et al. Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. , 2013, Research in veterinary science.
[128] S. Gygi,et al. The Energy Sensor AMP-activated Protein Kinase Directly Regulates the Mammalian FOXO3 Transcription Factor* , 2007, Journal of Biological Chemistry.
[129] S. Gygi,et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.
[130] Patrizia Sola,et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.
[131] C. Mammucari,et al. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models , 2011, Skeletal Muscle.
[132] C. Lang,et al. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. , 2007, American journal of physiology. Endocrinology and metabolism.
[133] H. S. Hundal,et al. Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin‐deficient mice , 2010, FEBS letters.
[134] A. Pestronk,et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.
[135] Se-Jin Lee,et al. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.
[136] N. Westerhof,et al. Diaphragm muscle fiber weakness in pulmonary hypertension. , 2011, American journal of respiratory and critical care medicine.
[137] A. Goldberg. Development of proteasome inhibitors as research tools and cancer drugs , 2012, The Journal of cell biology.
[138] A. Goldberg,et al. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. , 1999, The Journal of nutrition.
[139] D J Glass,et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.
[140] H. Hoppeler,et al. Performing at extreme altitude: muscle cellular and subcellular adaptations , 2003, European Journal of Applied Physiology.
[141] K. Fröhlich,et al. AAA-ATPase p97/Cdc48p, a Cytosolic Chaperone Required for Endoplasmic Reticulum-Associated Protein Degradation , 2002, Molecular and Cellular Biology.
[142] A. Goldberg,et al. FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.
[143] B. Spiegelman,et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.
[144] N. Iizuka,et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. , 1996, Cancer research.
[145] James R. Burke,et al. BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.
[146] B. Léger,et al. Antibody‐directed myostatin inhibition in 21‐mo‐old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[147] A. Oliff,et al. Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.
[148] N. LeBrasseur,et al. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[149] J. Dixon,et al. Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects , 2013, Obesity.
[150] J. Patrie,et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. , 2002, The Journal of clinical endocrinology and metabolism.
[151] Y. Jammes,et al. Maximal force and endurance to fatigue of respiratory and skeletal muscles in chronic hypoxemic patients: The effects of oxygen breathing , 1995, Muscle & nerve.
[152] S. Bhatnagar,et al. The E3 Ubiquitin Ligase TRAF6 Intercedes in Starvation-Induced Skeletal Muscle Atrophy through Multiple Mechanisms , 2012, Molecular and Cellular Biology.
[153] R. H. Migliorini,et al. Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. , 2007, American journal of physiology. Endocrinology and metabolism.
[154] R. Berdeaux,et al. cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. , 2012, American journal of physiology. Endocrinology and metabolism.
[155] S. Rakhilin,et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. , 2007, Cell metabolism.
[156] A. Russell,et al. Striated muscle activator of Rho signalling (STARS) is a PGC‐1α/oestrogen‐related receptor‐α target gene and is upregulated in human skeletal muscle after endurance exercise , 2011, The Journal of physiology.
[157] G. Biolo,et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.
[158] S. McGee,et al. Exercise and myocyte enhancer factor 2 regulation in human skeletal muscle. , 2004, Diabetes.
[159] E. Kudryashova,et al. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. , 2005, Journal of molecular biology.
[160] W. Mitch,et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. , 2004, The Journal of clinical investigation.
[161] Jiandie D. Lin,et al. PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.
[162] W. Mitch,et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[163] S. Anker,et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design , 2011, Journal of cachexia, sarcopenia and muscle.
[164] S. Anker,et al. Cardiac cachexia: a systematic overview. , 2009, Pharmacology & therapeutics.
[165] J. Rigas,et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer , 2011, Expert opinion on biological therapy.
[166] C. Lang,et al. Regulation of Myostatin by Glucocorticoids After Thermal Injury , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[167] L. Navegantes,et al. Phosphodiesterase‐4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles , 2011, Muscle & nerve.
[168] S. Roberts,et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. , 2010, The Journal of clinical endocrinology and metabolism.
[169] B. Nordestgaard,et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. , 2006, American journal of respiratory and critical care medicine.
[170] N. Banchero,et al. Effects of hypoxia on capillary density and fiber composition in rat skeletal muscle , 1977, Pflügers Archiv.
[171] L. Deldicque,et al. Prevention of muscle disuse atrophy by MG132 proteasome inhibitor , 2011, Muscle & nerve.
[172] Norbert Perrimon,et al. Mechanisms of skeletal muscle aging: insights from Drosophila and mammalian models , 2013, Disease Models & Mechanisms.
[173] B. Spiegelman,et al. Erratum: Increased muscle pgc-1αexpression protects from sarcopenia and metabolic disease during aging (Proceedings of the National Academy of Sciences of the United States of America (2009) 106 (20405-20410)) , 2014 .
[174] L. Tessitore,et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.
[175] C. Dogra,et al. TNF‐related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle‐wasting cytokine , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[176] D. Glass. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. , 2010, Current topics in microbiology and immunology.
[177] A. Goldberg,et al. Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. , 1988, The Journal of clinical investigation.
[178] A. Goldberg,et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[179] W. Mitch,et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. , 2013, Cell metabolism.
[180] Keiichi Fukuda,et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. , 2011, Cell metabolism.
[181] A. Goldberg,et al. The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins , 2012, The EMBO journal.
[182] R. Farràs,et al. Regulation and function of JunB in cell proliferation. , 2008, Biochemical Society transactions.
[183] P. Gluckman,et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice , 2011, Diabetologia.
[184] P. Stiuso,et al. Exercise training promotes SIRT1 activity in aged rats. , 2008, Rejuvenation research.
[185] G. Lanfranchi,et al. JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy , 2010, The Journal of cell biology.
[186] Q. Wang,et al. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation , 2012, The Journal of physiology.
[187] Keiji Tanaka,et al. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats. , 2002, The Biochemical journal.
[188] G. Lynch,et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.
[189] P. Hasselgren,et al. Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism. , 2010, The international journal of biochemistry & cell biology.
[190] M. Muscaritoli,et al. Increased Muscle Proteasome Activity Correlates With Disease Severity in Gastric Cancer Patients , 2003, Annals of surgery.
[191] C. Lang,et al. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[192] B. Spiegelman,et al. A PGC-1α Isoform Induced by Resistance Training Regulates Skeletal Muscle Hypertrophy , 2012, Cell.
[193] D. Walker,et al. Modulation of longevity and tissue homeostasis by the Drosophila PGC-1 homolog. , 2011, Cell metabolism.
[194] A. Russell. PGC-1α and Exercise: Important Partners in Combating Insulin Resistance , 2005 .
[195] M. Matzuk,et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[196] C. Y. Wang,et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.
[197] F. Maltais,et al. Atrophy and hypertrophy signalling of the quadriceps and diaphragm in COPD , 2010, Thorax.
[198] G. Lynch,et al. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. , 2008, Physiological reviews.
[199] S. Roth,et al. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. , 2003, American journal of physiology. Endocrinology and metabolism.
[200] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[201] S. Gygi,et al. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy , 2012, The Journal of cell biology.
[202] A. Dobs,et al. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. , 2009, Future oncology.
[203] B. Hamilton,et al. Growth factor delivery methods in the management of sports injuries: the state of play , 2007, British Journal of Sports Medicine.
[204] G. Strassmann,et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.
[205] I. Kettelhut,et al. Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt. , 2012, American journal of physiology. Endocrinology and metabolism.
[206] A. Goldberg,et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[207] D. Allen,et al. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors , 2007 .
[208] S. Welle,et al. Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure , 2010, Circulation.
[209] K. Tsuchida,et al. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. , 2009, American journal of physiology. Endocrinology and metabolism.
[210] Mi-Sung Kim,et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. , 2007, The Journal of clinical investigation.
[211] F. Haddad,et al. Combined isometric, concentric, and eccentric resistance exercise prevents unloading-induced muscle atrophy in rats. , 2007, Journal of applied physiology.
[212] Shalender Bhasin,et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[213] K. Rabe,et al. Phosphodiesterase-4 inhibitor therapy for lung diseases. , 2013, American journal of respiratory and critical care medicine.
[214] Shakir Ali,et al. Chronic hypobaric hypoxia mediated skeletal muscle atrophy: role of ubiquitin–proteasome pathway and calpains , 2012, Molecular and Cellular Biochemistry.
[215] Y. Lacasse,et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[216] A. Goldberg,et al. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[217] A. Goldberg,et al. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.
[218] Rick B. Vega,et al. The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor α in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes , 2000, Molecular and Cellular Biology.
[219] Stefano Piccolo,et al. BMP signaling controls muscle mass , 2013, Nature Genetics.
[220] M. Nakazato,et al. Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial , 2012, PloS one.
[221] Valentina Proserpio,et al. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy. , 2013, Genes & development.
[222] M. B. Bauer,et al. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy , 2005, Muscle & nerve.
[223] 山崎 芳浩. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle , 2010 .
[224] M. Wacker,et al. Contributions of the ubiquitin–proteasome pathway and apoptosis to human skeletal muscle wasting with age , 2005, Pflügers Archiv.
[225] K. Nakagawa,et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. , 2007, Urology.
[226] Jose M Garcia,et al. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[227] Jose M Garcia,et al. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study , 2012, Supportive Care in Cancer.
[228] A. Goldberg,et al. SIRT1 Protein, by Blocking the Activities of Transcription Factors FoxO1 and FoxO3, Inhibits Muscle Atrophy and Promotes Muscle Growth* , 2013, The Journal of Biological Chemistry.
[229] D. Sinclair,et al. Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.
[230] C. McArdle,et al. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. , 1996, British Journal of Cancer.
[231] J. E. Hurst,et al. Hindlimb unloading-induced muscle atrophy and loss of function: protective effect of isometric exercise. , 2003, Journal of applied physiology.
[232] R. Kambadur,et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[233] G. Yancopoulos,et al. Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy , 2004, Molecular and Cellular Biology.
[234] A. Goldberg,et al. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.
[235] E. Kudryashova,et al. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H. , 2012, The Journal of clinical investigation.
[236] B. Higgins,et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. , 2007, The Cochrane database of systematic reviews.
[237] V. Almendro,et al. Anticachectic Effects of Formoterol , 2004, Cancer Research.
[238] S. Bhatnagar,et al. Tumor Necrosis Factor-α Regulates Distinct Molecular Pathways and Gene Networks in Cultured Skeletal Muscle Cells , 2010, PloS one.
[239] R. Kurzrock,et al. Cytokines in pancreatic carcinoma , 2004, Cancer.
[240] Alan D. Lopez,et al. The Global Burden of Disease Study , 2003 .
[241] A. Goldberg,et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. , 2013, The international journal of biochemistry & cell biology.
[242] A. Goldberg,et al. The N-end Rule Pathway Catalyzes a Major Fraction of the Protein Degradation in Skeletal Muscle* , 1998, The Journal of Biological Chemistry.
[243] B. Spiegelman,et al. The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. , 2007, Cell metabolism.
[244] K. Yarasheski,et al. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. , 2002, The journal of nutrition, health & aging.
[245] F. Trensz,et al. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice , 2011, BMC musculoskeletal disorders.
[246] K. Wagner,et al. Muscle regeneration in the prolonged absence of myostatin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[247] A. Coats. Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. , 2002, International journal of cardiology.
[248] P. Costelli,et al. Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia. , 2003, International journal of oncology.
[249] G G Klee,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estroge , 2022 .
[250] Griffiths,et al. Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin , 1998, Neuropathology and applied neurobiology.
[251] L. Tessitore,et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. , 1996, Biochemical and biophysical research communications.
[252] P. Berger,et al. Hormonal changes in aging men: a therapeutic indication? , 2001, Experimental Gerontology.